RxDoctor Payments DataLook up a doctor →

Michael Cookson, MD

Urology · Oklahoma City, OKNPI 1528142635

Payments from drug & device makers

$657,936in general payments, 2019–2025

Across 248 payments — averaging $2652.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medivation LLC.$422K
  • Bayer$89K
  • Pfizer$45K
  • Astellas Pharma US Inc$30K
  • KARL Storz Endoscopy-america$17K
  • Merck$15K
  • plus $40K from 19 others

What the payments were for

  • Consulting fees$91,68869%
  • Speaking & faculty fees$24,81819%
  • Travel & lodging$11,9199%
  • Food & beverage$3,2402%
  • Education$3820%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$657,936 in reported general payments places this provider in the 95th percentile of 145 urology providers in Oklahoma.

See all urology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$254,792
Medicare patients
771
Services billed
1,668

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide155$2,096,459
ErleadaApalutamide16$236,928
NubeqaDarolutamide16$179,907
OrgovyxRelugolix64$160,450
Abiraterone Acetate27$5,781
Tamsulosin Hcl175$3,030
Dutasteride72$1,740
Finasteride66$1,307
Alfuzosin Hcl ErAlfuzosin Hcl51$1,172
NitrofurantoinNitrofurantoin Macrocrystal21$479
Imipramine Hcl27$418
Prednisone19$151
Solifenacin Succinate11$149
Ciprofloxacin Hcl13$129

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi$30,252$2,096,459155 claims
Johnson & JohnsonErleada$5,456$236,92816 claims
BayerNubeqa$88,683$179,90716 claims
Sumitomo Pharma America, Inc.Orgovyx$125$160,45064 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$6,567$5,78127 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 145 urology providers in Oklahoma.

Other urology in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →